论文部分内容阅读
目的:探讨非霍奇金淋巴瘤(NHL)患者的血清CA125水平及其临床应用价值。方法:用Elecsys法测定70例NHL患者初诊及治疗后的CA125水平,并将性别、分期、B症状、巨大包块、肿瘤负荷、浆膜腔积液、肿瘤浸润部位、血清乳酸脱氢酶(LDH)、国际预后指数评分(IPI)等预后因素及治疗反应进行相关性分析。结果:CA125水平与分期、B症状、巨大包块、肿瘤负荷、浆膜腔积液、肿瘤浸润部位、血清LDH、IPI等预后因素有相关性。CA125值高的NHL患者治疗失败率高,且容易复发(P <0.05 )。初诊时CA125值高的患者5 a生存率低。结论:血清CA125水平测定对NHL的病情监测及评价预后有临床意义。
Objective: To investigate the serum CA125 level in patients with non-Hodgkin’s lymphoma (NHL) and its clinical value. Methods: Seventy patients with NHL were enrolled and treated with Elecsys method to measure the level of CA125. The gender, stage, B symptoms, massive mass, tumor burden, serous effusion, tumor infiltration, serum lactate dehydrogenase LDH), international prognostic index (IPI) prognostic factors and treatment response correlation analysis. Results: The level of CA125 was correlated with the prognosis of staging, B symptoms, huge mass, tumor burden, serous effusion, tumor infiltration, serum LDH and IPI. NHL patients with high CA125 treatment failure rate is high, and easy to relapse (P <0.05). Patients with high CA125 at initial diagnosis had a 5-year survival rate. Conclusion: The determination of serum CA125 levels has clinical significance in the monitoring of disease and prognosis of NHL.